Sprintome
@sprintome.bsky.social
AI + Drug Discovery | Your front-row seat to the future of medicine
https://sprintome.substack.com
https://sprintome.substack.com
Pinned
Sprintome
@sprintome.bsky.social
· Apr 18
AI is no longer just a tool in the lab — it's becoming the lab.
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
Artificial intelligence is transforming biopharma by addressing major challenges like failure risk, high costs, and lengthy development timelines. PitchBook suggests AI will spark renewed VC interest in the biotech sector.
November 28, 2025 at 10:01 PM
Artificial intelligence is transforming biopharma by addressing major challenges like failure risk, high costs, and lengthy development timelines. PitchBook suggests AI will spark renewed VC interest in the biotech sector.
ARPA-H has launched a program to finance autonomous stroke-treating robots. The initiative is open to experts in surgery, imaging, and AI from academia and the private sector. Aiming to drive innovation in medtech.
November 28, 2025 at 8:00 PM
ARPA-H has launched a program to finance autonomous stroke-treating robots. The initiative is open to experts in surgery, imaging, and AI from academia and the private sector. Aiming to drive innovation in medtech.
💰 Cormorant Asset Management sets sights on raising $400M for new healthcare fund. The Boston-based biotech investor has already started the fundraising process this month. Exciting times ahead for Cormorant!
November 28, 2025 at 1:00 PM
💰 Cormorant Asset Management sets sights on raising $400M for new healthcare fund. The Boston-based biotech investor has already started the fundraising process this month. Exciting times ahead for Cormorant!
AstraZeneca's Imfinzi receives FDA approval for perioperative treatment in stomach cancers, marking a significant label extension. The PD-L1 inhibitor...
November 27, 2025 at 10:00 PM
AstraZeneca's Imfinzi receives FDA approval for perioperative treatment in stomach cancers, marking a significant label extension. The PD-L1 inhibitor...
🚨 Sanofi's headquarters raided in French tax fraud investigation. Authorities probe alleged tax fraud involving multiple companies. Raid part of broader investigation by French authorities.
November 27, 2025 at 8:00 PM
🚨 Sanofi's headquarters raided in French tax fraud investigation. Authorities probe alleged tax fraud involving multiple companies. Raid part of broader investigation by French authorities.
Sarepta receives positive safety update for DM1 asset, leading to $200M milestone payment to Arrowhead. Enrolled study meets target, showcasing advancements in RNA medicine.
November 27, 2025 at 4:43 PM
Sarepta receives positive safety update for DM1 asset, leading to $200M milestone payment to Arrowhead. Enrolled study meets target, showcasing advancements in RNA medicine.
🔬 Breakthrough in brain tissue imaging: All-optical visualization of specific molecules achieved through pan-expansion microscopy. Published in Nature Biotechnology, this technique combines protein and lipid staining with immunolabeling.
November 27, 2025 at 3:54 PM
🔬 Breakthrough in brain tissue imaging: All-optical visualization of specific molecules achieved through pan-expansion microscopy. Published in Nature Biotechnology, this technique combines protein and lipid staining with immunolabeling.
A potential UK-US drug pricing agreement may be confirmed this week per UK sources. This deal could have significant implications for pharmaceutical pricing strategies in both nations.
November 26, 2025 at 1:19 AM
A potential UK-US drug pricing agreement may be confirmed this week per UK sources. This deal could have significant implications for pharmaceutical pricing strategies in both nations.
💰 Solventum acquires Acera Surgical for up to $850M, marking its first major acquisition. The deal strengthens Solventum's position in the wound care market, showcasing a strategic growth move.
November 26, 2025 at 1:09 AM
💰 Solventum acquires Acera Surgical for up to $850M, marking its first major acquisition. The deal strengthens Solventum's position in the wound care market, showcasing a strategic growth move.
🌟 Big news at #ASH25 as Kelonia presents first in vivo CAR-T data. Meanwhile, Lilly, J&J, and Novartis reveal Phase 3 victories. Abstracts dropped early, surprising attendees pre-Thanksgiving.
November 26, 2025 at 12:44 AM
🌟 Big news at #ASH25 as Kelonia presents first in vivo CAR-T data. Meanwhile, Lilly, J&J, and Novartis reveal Phase 3 victories. Abstracts dropped early, surprising attendees pre-Thanksgiving.
🔥 Arsenal Biosciences slashes workforce by 50% to optimize resources. CEO Ken Drazan confirms the major move by the well-funded cell therapy startup. Restructuring aims to enhance focus on core initiatives.
September 18, 2025 at 3:24 PM
🔥 Arsenal Biosciences slashes workforce by 50% to optimize resources. CEO Ken Drazan confirms the major move by the well-funded cell therapy startup. Restructuring aims to enhance focus on core initiatives.
City Therapeutics receives significant early-stage funding for their novel application of cityRNAs in siRNA therapeutics. Nature Biotechnology highlights their innovative strategy in the biotech sector.
September 18, 2025 at 11:31 AM
City Therapeutics receives significant early-stage funding for their novel application of cityRNAs in siRNA therapeutics. Nature Biotechnology highlights their innovative strategy in the biotech sector.
🏆 Regeneron triumphs with phase 3 success in ultrarare disease, fueling FDA race. Garetosmab for fibrodysplasia ossificans progressiva set for approval filing by end of 2025 after pivotal trial victory.
September 18, 2025 at 11:12 AM
🏆 Regeneron triumphs with phase 3 success in ultrarare disease, fueling FDA race. Garetosmab for fibrodysplasia ossificans progressiva set for approval filing by end of 2025 after pivotal trial victory.
💰 Ollin Biosciences launches with $100M, aiming to challenge Roche's eye disease dominance. Co-founder Jason Ehrlich, once at Genentech, now leads the charge with a Chinese-sourced antibody. A showdown is on the horizon!
September 18, 2025 at 10:55 AM
💰 Ollin Biosciences launches with $100M, aiming to challenge Roche's eye disease dominance. Co-founder Jason Ehrlich, once at Genentech, now leads the charge with a Chinese-sourced antibody. A showdown is on the horizon!
💰 GSK unveils massive $30B investment plan for U.S. R&D and manufacturing. British pharma giant joins American investment wave. Major boost for the industry and economy!
September 18, 2025 at 12:48 AM
💰 GSK unveils massive $30B investment plan for U.S. R&D and manufacturing. British pharma giant joins American investment wave. Major boost for the industry and economy!
Affini-T Therapeutics faces potential shutdown as CEO departs. Last senior executive's exit raises questions about company's future. Biotech's focus on cell therapies for solid tumors now in jeopardy.
September 18, 2025 at 12:47 AM
Affini-T Therapeutics faces potential shutdown as CEO departs. Last senior executive's exit raises questions about company's future. Biotech's focus on cell therapies for solid tumors now in jeopardy.
🌟 Eli Lilly's orforglipron outperforms Novo Nordisk's Rybelsus in diabetes trial! Lilly considers fast-track filing for its obesity pill. Exciting developments in the competitive diabetes market.
September 18, 2025 at 12:43 AM
🌟 Eli Lilly's orforglipron outperforms Novo Nordisk's Rybelsus in diabetes trial! Lilly considers fast-track filing for its obesity pill. Exciting developments in the competitive diabetes market.
💰 Dualitas secures a whopping $65M in venture capital funding, while AllRock raises a solid $50M. The Fierce Biotech Fundraising Tracker highlights major investments in biotech.
September 16, 2025 at 7:59 PM
💰 Dualitas secures a whopping $65M in venture capital funding, while AllRock raises a solid $50M. The Fierce Biotech Fundraising Tracker highlights major investments in biotech.
🚨 FDA flags AstraZeneca's flu vaccine TV ad in regulatory crackdown. Letter dated Sept. 9 calls out 60-second FluMist ad for misleading claims. Part of wider scrutiny on pharma commercials.
September 16, 2025 at 12:39 PM
🚨 FDA flags AstraZeneca's flu vaccine TV ad in regulatory crackdown. Letter dated Sept. 9 calls out 60-second FluMist ad for misleading claims. Part of wider scrutiny on pharma commercials.
💰 AstraZeneca halts $271M expansion in UK, joining other Big Pharma companies scaling back in Britain. The decision impacts the Cambridge research site, reflecting a broader trend in the industry.
September 16, 2025 at 12:38 AM
💰 AstraZeneca halts $271M expansion in UK, joining other Big Pharma companies scaling back in Britain. The decision impacts the Cambridge research site, reflecting a broader trend in the industry.
HHS Secretary Robert F. Kennedy Jr. has added 5 new members to the Advisory Committee on Immunization Practices in preparation for an upcoming critical meeting. The panel's decisions could have significant implications for immunization strategies.
September 15, 2025 at 11:07 PM
HHS Secretary Robert F. Kennedy Jr. has added 5 new members to the Advisory Committee on Immunization Practices in preparation for an upcoming critical meeting. The panel's decisions could have significant implications for immunization strategies.
📉 aTyr Pharma's stock plummets 80% after Phase 3 failure in pulmonary sarcoidosis trial. Investor confidence shaken as {$ATYR} shares crash at market open. Company faces challenges ahead.
September 15, 2025 at 11:03 PM
📉 aTyr Pharma's stock plummets 80% after Phase 3 failure in pulmonary sarcoidosis trial. Investor confidence shaken as {$ATYR} shares crash at market open. Company faces challenges ahead.
💰 Galimedix gears up for phase 2 funding round as oral Alzheimer's candidate passes safety test. Small molecule shows no serious adverse events and penetrates blood-brain barrier successfully. Maryland-based biotech poised for next stage of development.
September 15, 2025 at 10:44 PM
💰 Galimedix gears up for phase 2 funding round as oral Alzheimer's candidate passes safety test. Small molecule shows no serious adverse events and penetrates blood-brain barrier successfully. Maryland-based biotech poised for next stage of development.
💰 Novartis seals $120M deal with Monte Rosa Therapeutics for immune degraders. Swiss pharma giant's deal spree continues, with total biobucks value exceeding $5.7B. Partnership set to advance innovative therapies.
September 15, 2025 at 10:44 PM
💰 Novartis seals $120M deal with Monte Rosa Therapeutics for immune degraders. Swiss pharma giant's deal spree continues, with total biobucks value exceeding $5.7B. Partnership set to advance innovative therapies.
🚨 US government criticizes mRNA vaccine research in recent report. Findings published in Nature Biotechnology highlight concerns. Impact on future funding and regulatory decisions uncertain.
September 15, 2025 at 10:40 PM
🚨 US government criticizes mRNA vaccine research in recent report. Findings published in Nature Biotechnology highlight concerns. Impact on future funding and regulatory decisions uncertain.